Related Experiment Videos
GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting
D Dondi1, C Festuccia, M Piccolella
1Department of Endocrinology, Center of Endocrinological Oncology, University of Milano, Via Balzaretti 9, 20133 Milano, Italy. donatella.dondi@unimi.it
Oncology Reports
|January 5, 2006
Summary
Gonadotropin-releasing hormone (GnRH) agonists and antagonists reduce prostate cancer cell proliferation and metastasis by inhibiting urokinase-type plasminogen activator (uPA) activity and increasing its inhibitor (PAI-1). These findings support GnRH analogues as treatments for advanced prostate cancer.
Area of Science:
- Oncology
- Endocrinology
- Biochemistry
Background:
- Prostate cancer (PCa) growth is initially androgen-dependent, but it progresses to an androgen-independent, metastatic state.
- Gonadotropin-releasing hormone (GnRH) analogues are used to treat PCa, but resistance develops.
- The plasminogen activator (PA) system, including urokinase-type PA (uPA) and its inhibitor PAI-1, is involved in extracellular matrix degradation and cancer progression.
Purpose of the Study:
- To investigate the effects of GnRH agonist (Leuprolide) and antagonist (Cetrorelix) on uPA and PAI-1 in androgen-independent PCa cell lines (DU145, PC3).
- To assess the impact of GnRH analogues on the migratory and invasive potential of PCa cells, mediated by the PA system.
Main Methods:
- Treatment of DU145 and PC3 prostate cancer cell lines with GnRH agonist (GnRH-A) and GnRH antagonist (GnRH-ANT).
- Measurement of cell proliferation, uPA enzymatic activity, uPA secretion, and PAI-1 protein levels in conditioned media.
- Evaluation of cellular migration and invasion capabilities.
Main Results:
- Both GnRH-A and GnRH-ANT significantly inhibited cell proliferation in DU145 and PC3 cells.
- GnRH analogues markedly decreased uPA enzymatic activity and secretion.
- Treatment with GnRH analogues led to a significant increase in PAI-1 protein levels.
- GnRH analogues significantly reduced the migratory and invasive potential of PCa cells.
Conclusions:
- GnRH analogues demonstrate antiproliferative effects on androgen-independent prostate cancer cells.
- GnRH analogues possess anti-metastatic properties by inhibiting the PA system's activity.
- These findings suggest GnRH analogues could be a therapeutic strategy for advanced, metastatic prostate cancer with potential clinical applications.